call 1800 257 600 email [email protected]

Clinical Trials

Cancer Type

State

Phase

Treatment

Inhibitor

A clinical trial to assess the safety, distribution, effects on certain immune cells and anti-leukaemia effects of LAVA-1266 in patients with acute myeloid leukaemia or certain types of myelodysplastic syndrome

ACTRN 12624001214527 Brief Summary This study is a first in human (FIH)…

Read more arrow_forward

A phase 1 study to assess the safety of short-course treatment with venetoclax prior to non-myeloablative stem cell transplantation for patients with haematological malignancies.

ACTRN 12622000308796 Brief Summary The purpose of this study is to investigate…

Read more arrow_forward

A Study of BGB-11417 in Participants With Myeloid Malignancies

NCT 04771130 Brief Summary The study will determine the safety, tolerability, recommended…

Read more arrow_forward

A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

NCT 06456463 Brief Summary This study will be divided into 2 parts…

Read more arrow_forward

A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies

NCT 06508489 Brief Summary This is a parallel, Phase 1/Phase 2, randomized,…

Read more arrow_forward

AMLM26/T1 INTERCEPT: A multi-arm trial for patients with acute myeloid leukaemia investigating new treatments which target early relapse and changes in disease characteristics – Gilteritinib+ Venetoclax

ACTRN 12624000082505 Brief Summary This is a combined drug treatment arm within…

Read more arrow_forward

AMLM26/T3 INTERCEPT: A multi-arm trial for patients with acute myeloid leukaemia investigating new treatments which target early relapse and changes in disease characteristics – Low-dose cytarabine (LDAC) + Venetoclax

ACTRN 12624000006549 Brief Summary This is a combination drug treatment arm within…

Read more arrow_forward

AMLM26/T4- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in Acute Myeloid Leukaemia (AML)): A Multi-arm, Precision-based, Recursive, Platform Trial – SNDX5613

ACTRN 12622000582752 Brief Summary This is an investigational agent within the ALLG…

Read more arrow_forward

AMLM26/T5- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in Acute Myeloid Leukaemia (AML)): A Multi-arm, Precision-based, Recursive, Platform Trial – MBG453 OR MBG453 and Azacitidine

ACTRN 12621001265864 Brief Summary This is an investigational agent within the ALLG…

Read more arrow_forward

First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

NCT 05086315 Brief Summary This is an open-label, multicenter, Phase 1/Phase 2,…

Read more arrow_forward

Knowledge Base

Cancer Types Cancer Services Health Professionals

How we help you

Our support knows no limits, which means we do whatever it takes to be there for all you need.

How we help you View the Rare Cancer Support Guide

Can’t find what you’re looking for?

We have a friendly team available to chat about any questions you may have, or just to lend an ear if you’re having a tough time.

Call 1800 257 600 Have us call you